BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST
Bergen, Norway, 18 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the first quarter 2022 on Tuesday 24 May 2022. A presentation and live webcast by BerGenBio’s senior management team will take place at 10:00 am CET, followed by a Q&A session. The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section and a recording will be available shortly after the webcast has finished. The